DRV/r + RPV QD: Efficacy and Toxicity Reduction

Condition:   Human Immunodeficiency VirusInterventions:   Drug: RPV + DRV/r;   Drug: continue the PI/r-containing HAART.Sponsors:   Ospedale L. Sacco – Polo Universitario;   Elisa Colella, M.D.;   Valentina Di Cristo, M.D.;   Massimo Galli, M.D.Recruiting - verified October 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials